Search Results

You are looking at 41 - 43 of 43 items for :

  • "kidney disease" x
Clear All
Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas and Catherine H. Van Poznak

in patients with stage IV or V chronic kidney disease unless adynamic bone disease or other forms of chronic kidney disease and bone mineral disorder have been ruled out. Unlike the bisphosphonates, denosumab is not excreted through the kidneys. 340

Full access

Ayman Saad, Marcos de Lima, Sarah Anand, Vijaya Raj Bhatt, Ryan Bookout, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Sergio Giralt, Jonathan Gutman, Vincent Ho, Mitchell Horwitz, Joe Hsu, Mark Juckett, Mohamed Kharfan Dabaja, Alison W. Loren, MSCE, Javier Meade, Marco Mielcarek, Jonathan Moreira, Ryotaro Nakamura, Yago Nieto, Julianna Roddy, Gowri Satyanarayana, Mark Schroeder, Carlyn Rose Tan, Dimitrios Tzachanis, Jennifer L. Burns and Lenora A. Pluchino

Chronic Kidney Disease, Dialysis, and Transplantation , 3rd Ed . Philadelphia, PA: W.B. Saunders ; 2010 . 159. Hsieh A . mTOR: the master regulator . Cell 2012 ; 149 : 955 – 957 . 160. Dumont

Full access

not qualify due to chronic kidney disease. Therefore, 9 patients agreed to undergo IP chemotherapy and 5 completed the proposed number of cycles (55%). Abdominal pain caused 2 patients to discontinue IP early, 1 developed pneumatosis intestinalis, and